Literature DB >> 25612003

Pathologic Regulation of Collagen I by an Aberrant Protein Phosphatase 2A/Histone Deacetylase C4/MicroRNA-29 Signal Axis in Idiopathic Pulmonary Fibrosis Fibroblasts.

Wajahat Khalil1, Hong Xia1, Vidya Bodempudi1, Judy Kahm1, Polla Hergert1, Karen Smith1, Mark Peterson1, Matthew Parker1, Jeremy Herrera1, Peter B Bitterman1, Craig A Henke1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by the relentless expansion of fibroblasts depositing type I collagen within the alveolar wall and obliterating the alveolar airspace. MicroRNA (miR)-29 is a potent regulator of collagen expression. In IPF, miR-29 levels are low, whereas type I collagen expression is high. However, the mechanism for suppression of miR-29 and increased type I collagen expression in IPF remains unclear. Here we show that when IPF fibroblasts are seeded on polymerized type I collagen, miR-29c levels are suppressed and type I collagen expression is high. In contrast, miR-29c is high and type I collagen expression is low in control fibroblasts. We demonstrate that the mechanism for suppression of miR-29 during IPF fibroblast interaction with polymerized collagen involves inappropriately low protein phosphatase (PP) 2A function, leading to histone deacetylase (HDA) C4 phosphorylation and decreased nuclear translocation of HDAC4. We demonstrate that overexpression of HDAC4 in IPF fibroblasts restored miR-29c levels and decreased type I collagen expression, whereas knocking down HDAC4 in control fibroblasts suppressed miR-29c levels and increased type I collagen expression. Our data indicate that IPF fibroblast interaction with polymerized type I collagen results in an aberrant PP2A/HDAC4 axis, which suppresses miR-29, causing a pathologic increase in type I collagen expression.

Entities:  

Keywords:  HDAC4; IPF fibroblasts; PP2A; miR-29; type I collagen

Mesh:

Substances:

Year:  2015        PMID: 25612003      PMCID: PMC4566061          DOI: 10.1165/rcmb.2014-0150OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  48 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

3.  Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction.

Authors:  Xiangwei Huang; Naiheng Yang; Vincent F Fiore; Thomas H Barker; Yi Sun; Stephan W Morris; Qiang Ding; Victor J Thannickal; Yong Zhou
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-29       Impact factor: 6.914

4.  HDAC4 deacetylase associates with and represses the MEF2 transcription factor.

Authors:  E A Miska; C Karlsson; E Langley; S J Nielsen; J Pines; T Kouzarides
Journal:  EMBO J       Date:  1999-09-15       Impact factor: 11.598

Review 5.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

6.  Caspase-mediated specific cleavage of human histone deacetylase 4.

Authors:  Fang Liu; Melissa Dowling; Xiang-Jiao Yang; Gary D Kao
Journal:  J Biol Chem       Date:  2004-06-17       Impact factor: 5.157

7.  HDAC4 promotes growth of colon cancer cells via repression of p21.

Authors:  Andrew J Wilson; Do-Sun Byun; Shannon Nasser; Lucas B Murray; Kanyalakshmi Ayyanar; Diego Arango; Maria Figueroa; Ari Melnick; Gary D Kao; Leonard H Augenlicht; John M Mariadason
Journal:  Mol Biol Cell       Date:  2008-07-16       Impact factor: 4.138

8.  Fibrotic extracellular matrix activates a profibrotic positive feedback loop.

Authors:  Matthew W Parker; Daniel Rossi; Mark Peterson; Karen Smith; Kristina Sikström; Eric S White; John E Connett; Craig A Henke; Ola Larsson; Peter B Bitterman
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

9.  Class IIa histone deacetylases and myocyte enhancer factor 2 proteins regulate the mesenchymal-to-epithelial transition of somatic cell reprogramming.

Authors:  Qiang Zhuang; Xiaobing Qing; Yue Ying; Haitao Wu; Christina Benda; Jiao Lin; Zhijian Huang; Longqi Liu; Yan Xu; Xichen Bao; Baoming Qin; Duanqing Pei; Miguel A Esteban
Journal:  J Biol Chem       Date:  2013-03-06       Impact factor: 5.157

10.  PP2A regulates HDAC4 nuclear import.

Authors:  Gabriela Paroni; Nadia Cernotta; Claudio Dello Russo; Paola Gallinari; Michele Pallaoro; Carmela Foti; Fabio Talamo; Laura Orsatti; Christian Steinkühler; Claudio Brancolini
Journal:  Mol Biol Cell       Date:  2007-11-28       Impact factor: 4.138

View more
  15 in total

Review 1.  The role of microRNAs in chronic respiratory disease: recent insights.

Authors:  Lindsay R Stolzenburg; Ann Harris
Journal:  Biol Chem       Date:  2018-02-23       Impact factor: 3.915

2.  TGF-β1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts.

Authors:  Weichao Guo; Shigeki Saito; Cecilia G Sanchez; Yan Zhuang; Rafael E Gongora Rosero; Bin Shan; Fayong Luo; Joseph A Lasky
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-03-23       Impact factor: 5.464

3.  MicroRNA-29c Prevents Pulmonary Fibrosis by Regulating Epithelial Cell Renewal and Apoptosis.

Authors:  Ting Xie; Jiurong Liang; Yan Geng; Ningshan Liu; Adrianne Kurkciyan; Vrishika Kulur; Dong Leng; Nan Deng; Zhenqiu Liu; Jianbo Song; Peter Chen; Paul W Noble; Dianhua Jiang
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

4.  TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression.

Authors:  Dakota L Jones; Andrew J Haak; Nunzia Caporarello; Kyoung M Choi; Zhenqing Ye; Huihuang Yan; Xaralabos Varelas; Tamas Ordog; Giovanni Ligresti; Daniel J Tschumperlin
Journal:  J Cell Sci       Date:  2019-10-18       Impact factor: 5.285

5.  Simvastatin reduces TGF-β1-induced SMAD2/3-dependent human ventricular fibroblasts differentiation: Role of protein phosphatase activation.

Authors:  Farhan Rizvi; Ramail Siddiqui; Alessandra DeFranco; Peter Homar; Larisa Emelyanova; Ekhson Holmuhamedov; Gracious Ross; A Jamil Tajik; Arshad Jahangir
Journal:  Int J Cardiol       Date:  2018-06-21       Impact factor: 4.164

Review 6.  MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics.

Authors:  Huimin Li; Xiaoguang Zhao; Hongli Shan; Haihai Liang
Journal:  Acta Pharm Sin B       Date:  2016-07-27       Impact factor: 11.413

7.  Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function.

Authors:  Ayodeji Adegunsoye; Cara L Hrusch; Catherine A Bonham; Mohammad R Jaffery; Kelly M Blaine; Meghan Sullivan; Matthew M Churpek; Mary E Strek; Imre Noth; Anne I Sperling
Journal:  Front Immunol       Date:  2016-11-23       Impact factor: 7.561

8.  Endoplasmic reticulum stress enhances fibrosis through IRE1α-mediated degradation of miR-150 and XBP-1 splicing.

Authors:  Femke Heindryckx; François Binet; Markella Ponticos; Krista Rombouts; Joey Lau; Johan Kreuger; Pär Gerwins
Journal:  EMBO Mol Med       Date:  2016-07-01       Impact factor: 12.137

9.  Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics.

Authors:  Feng Yan; Zhensong Wen; Rui Wang; Wenling Luo; Yufeng Du; Wenjun Wang; Xianyang Chen
Journal:  BMC Pulm Med       Date:  2017-12-06       Impact factor: 3.317

Review 10.  HDAC4 in ischemic stroke: mechanisms and therapeutic potential.

Authors:  Qingsheng Kong; Yongnan Hao; Xin Li; Xin Wang; Bingyuan Ji; Yili Wu
Journal:  Clin Epigenetics       Date:  2018-09-12       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.